Cargando…

Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite

BACKGROUND: The intercalation of perindopril erbumine into Zn/Al-NO(3)-layered double hydroxide resulted in the formation of a host-guest type of material. By virtue of the ion-exchange properties of layered double hydroxide, perindopril erbumine was released in a sustained manner. Therefore, this i...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Ali, Samer Hasan Hussein, Al-Qubaisi, Mothanna, Hussein, Mohd Zobir, Ismail, Maznah, Zainal, Zulkarnain, Hakim, Muhammad Nazrul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356206/
https://www.ncbi.nlm.nih.gov/pubmed/22619549
http://dx.doi.org/10.2147/IJN.S30461
_version_ 1782233520292233216
author Al Ali, Samer Hasan Hussein
Al-Qubaisi, Mothanna
Hussein, Mohd Zobir
Ismail, Maznah
Zainal, Zulkarnain
Hakim, Muhammad Nazrul
author_facet Al Ali, Samer Hasan Hussein
Al-Qubaisi, Mothanna
Hussein, Mohd Zobir
Ismail, Maznah
Zainal, Zulkarnain
Hakim, Muhammad Nazrul
author_sort Al Ali, Samer Hasan Hussein
collection PubMed
description BACKGROUND: The intercalation of perindopril erbumine into Zn/Al-NO(3)-layered double hydroxide resulted in the formation of a host-guest type of material. By virtue of the ion-exchange properties of layered double hydroxide, perindopril erbumine was released in a sustained manner. Therefore, this intercalated material can be used as a controlled-release formulation. RESULTS: Perindopril was intercalated into the interlayers and formed a well ordered, layered organic-inorganic nanocomposite. The basal spacing of the products was expanded to 21.7 Å and 19.9 Å by the ion-exchange and coprecipitation methods, respectively, in a bilayer and a monolayer arrangement, respectively. The release of perindopril from the nanocomposite synthesized by the coprecipitation method was slower than that of its counterpart synthesized by the ion-exchange method. The rate of release was governed by pseudo-second order kinetics. An in vitro antihypertensive assay showed that the intercalation process results in effectiveness similar to that of the antihypertensive properties of perindopril. CONCLUSION: Intercalated perindopril showed better thermal stability than its free counterpart. The resulting material showed sustained-release properties and can therefore be used as a controlled-release formulation.
format Online
Article
Text
id pubmed-3356206
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-33562062012-05-22 Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite Al Ali, Samer Hasan Hussein Al-Qubaisi, Mothanna Hussein, Mohd Zobir Ismail, Maznah Zainal, Zulkarnain Hakim, Muhammad Nazrul Int J Nanomedicine Original Research BACKGROUND: The intercalation of perindopril erbumine into Zn/Al-NO(3)-layered double hydroxide resulted in the formation of a host-guest type of material. By virtue of the ion-exchange properties of layered double hydroxide, perindopril erbumine was released in a sustained manner. Therefore, this intercalated material can be used as a controlled-release formulation. RESULTS: Perindopril was intercalated into the interlayers and formed a well ordered, layered organic-inorganic nanocomposite. The basal spacing of the products was expanded to 21.7 Å and 19.9 Å by the ion-exchange and coprecipitation methods, respectively, in a bilayer and a monolayer arrangement, respectively. The release of perindopril from the nanocomposite synthesized by the coprecipitation method was slower than that of its counterpart synthesized by the ion-exchange method. The rate of release was governed by pseudo-second order kinetics. An in vitro antihypertensive assay showed that the intercalation process results in effectiveness similar to that of the antihypertensive properties of perindopril. CONCLUSION: Intercalated perindopril showed better thermal stability than its free counterpart. The resulting material showed sustained-release properties and can therefore be used as a controlled-release formulation. Dove Medical Press 2012 2012-04-24 /pmc/articles/PMC3356206/ /pubmed/22619549 http://dx.doi.org/10.2147/IJN.S30461 Text en © 2012 Hussein Al Ali et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Al Ali, Samer Hasan Hussein
Al-Qubaisi, Mothanna
Hussein, Mohd Zobir
Ismail, Maznah
Zainal, Zulkarnain
Hakim, Muhammad Nazrul
Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite
title Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite
title_full Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite
title_fullStr Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite
title_full_unstemmed Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite
title_short Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite
title_sort controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356206/
https://www.ncbi.nlm.nih.gov/pubmed/22619549
http://dx.doi.org/10.2147/IJN.S30461
work_keys_str_mv AT alalisamerhasanhussein controlledreleaseandangiotensinconvertingenzymeinhibitionpropertiesofanantihypertensivedrugbasedonaperindoprilerbuminelayereddoublehydroxidenanocomposite
AT alqubaisimothanna controlledreleaseandangiotensinconvertingenzymeinhibitionpropertiesofanantihypertensivedrugbasedonaperindoprilerbuminelayereddoublehydroxidenanocomposite
AT husseinmohdzobir controlledreleaseandangiotensinconvertingenzymeinhibitionpropertiesofanantihypertensivedrugbasedonaperindoprilerbuminelayereddoublehydroxidenanocomposite
AT ismailmaznah controlledreleaseandangiotensinconvertingenzymeinhibitionpropertiesofanantihypertensivedrugbasedonaperindoprilerbuminelayereddoublehydroxidenanocomposite
AT zainalzulkarnain controlledreleaseandangiotensinconvertingenzymeinhibitionpropertiesofanantihypertensivedrugbasedonaperindoprilerbuminelayereddoublehydroxidenanocomposite
AT hakimmuhammadnazrul controlledreleaseandangiotensinconvertingenzymeinhibitionpropertiesofanantihypertensivedrugbasedonaperindoprilerbuminelayereddoublehydroxidenanocomposite